Rifaximin in Fatty Liver Disease (RiFL)

This study has been terminated.
(Review of primary endpoint data by study Investigators concluded no further patients required.)
Sponsor:
Collaborator:
National Health Service, United Kingdom
Information provided by (Responsible Party):
Imperial College London
ClinicalTrials.gov Identifier:
NCT01355575
First received: May 17, 2011
Last updated: October 16, 2012
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: September 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)